11-108332024-C-G

Variant summary

Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM1PP3_Moderate

The NM_000051.4(ATM):ā€‹c.7775C>Gā€‹(p.Ser2592Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000304 in 1,613,728 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā˜…ā˜…). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S2592P) has been classified as Uncertain significance.

Frequency

Genomes: š‘“ 0.000020 ( 0 hom., cov: 32)
Exomes š‘“: 0.000031 ( 0 hom. )

Consequence

ATM
NM_000051.4 missense

Scores

7
7
5

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts P:1U:9

Conservation

PhyloP100: 6.03
Variant links:
Genes affected
ATM (HGNC:795): (ATM serine/threonine kinase) The protein encoded by this gene belongs to the PI3/PI4-kinase family. This protein is an important cell cycle checkpoint kinase that phosphorylates; thus, it functions as a regulator of a wide variety of downstream proteins, including tumor suppressor proteins p53 and BRCA1, checkpoint kinase CHK2, checkpoint proteins RAD17 and RAD9, and DNA repair protein NBS1. This protein and the closely related kinase ATR are thought to be master controllers of cell cycle checkpoint signaling pathways that are required for cell response to DNA damage and for genome stability. Mutations in this gene are associated with ataxia telangiectasia, an autosomal recessive disorder. [provided by RefSeq, Aug 2010]
C11orf65 (HGNC:28519): (chromosome 11 open reading frame 65) Predicted to be involved in negative regulation of mitochondrial fission and negative regulation of protein targeting to mitochondrion. Predicted to be located in cytosol and mitochondrial outer membrane. [provided by Alliance of Genome Resources, Apr 2022]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got 4 ACMG points.

PM1
In a hotspot region, there are 3 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 2 benign, 14 uncertain in NM_000051.4
PP3
MetaRNN computational evidence supports a deleterious effect, 0.909

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
ATMNM_000051.4 linkuse as main transcriptc.7775C>G p.Ser2592Cys missense_variant 52/63 ENST00000675843.1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
ATMENST00000675843.1 linkuse as main transcriptc.7775C>G p.Ser2592Cys missense_variant 52/63 NM_000051.4 P1

Frequencies

GnomAD3 genomes
AF:
0.0000197
AC:
3
AN:
152172
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000441
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000159
AC:
4
AN:
250918
Hom.:
0
AF XY:
0.00000737
AC XY:
1
AN XY:
135612
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000265
Gnomad OTH exome
AF:
0.000164
GnomAD4 exome
AF:
0.0000315
AC:
46
AN:
1461556
Hom.:
0
Cov.:
31
AF XY:
0.0000330
AC XY:
24
AN XY:
727088
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000414
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
AF:
0.0000197
AC:
3
AN:
152172
Hom.:
0
Cov.:
32
AF XY:
0.00
AC XY:
0
AN XY:
74334
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000441
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.0000282
Hom.:
0
Bravo
AF:
0.0000302
ExAC
AF:
0.0000247
AC:
3

ClinVar

Significance: Uncertain significance
Submissions summary: Pathogenic:1Uncertain:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Hereditary cancer-predisposing syndrome Pathogenic:1Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthJan 08, 2024This missense variant replaces serine with cysteine at codon 2592 of the ATM protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function. A functional study has reported that this variant protein has no detectable kinase activity and fails to rescue the elevated radiosensitivity and chromosome aberration phenotype in ATM-deficient cells (PMID: 11805335). This variant has been observed in individuals affected with breast cancer (PMID: 11606401, 19781682, 26898890, 28779002), prostate cancer (PMID: 28825054), non-Hodgkin lymphoma (PMID: 17640065) and multiple primary tumors (PMID: 29909963) and in an unaffected control in a breast cancer case-control study (PMID: 28779002). In a separate, international case-control meta-analysis, this variant was reported in 4/60466 breast cancer cases and 6/53461 controls (OR=0.589, 95%CI 0.166 to 2.089, p-value=0.531; PMID: 33471991). This variant has been identified in 4/250918 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsApr 18, 2024The p.S2592C variant (also known as c.7775C>G), located in coding exon 51 of the ATM gene, results from a C to G substitution at nucleotide position 7775. The serine at codon 2592 is replaced by cysteine, an amino acid with dissimilar properties. This alteration has been identified in an individual diagnosed with ataxia telangiectasia; however a second ATM alteration was not documented (Neubauer S et al. Radiat Res, 2002 Mar;157:312-21). This alteration has been reported in 1/4,112 breast cancer cases and 0/2,399 controls in a meta-analysis of the role of the ATM gene in breast cancer susceptibility (Tavtigian SV et al. Am. J. Hum. Genet. 2009 Oct;85:427-46). This variant has also been detected in cohorts of patients with non-Hodgkin lymphoma, multiple primary tumors, and prostate cancer (Sipahimalani P et al. Int. J. Cancer. 2007 Nov;121:1967-75; Abida W et al. JCO Precis Oncol. 2017 Jul;2017; Whitworth J et al. Am. J. Hum. Genet. 2018 Jul;103:3-18; Karlsson Q et al. Eur Urol Oncol, 2021 Aug;4:570-579). In functional studies, this variant demonstrated an absence of kinase activity in vivo and in vitro, and increased sensitivity to ionizing radiation (Scott SP et al. Proc. Natl. Acad. Sci. U.S.A. 2002 Jan;99:925-30). Scott et al. also demonstrated the ability of the p.S2592C variant to interfere with wild-type kinase activity in a dominant negative fashion. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Likely pathogenic, flagged submissionresearchAcademic Department of Medical Genetics, University of CambridgeJan 26, 2018Application of AMCG guidelines 2015. Used other ClinVar submission evidence where relevant. Loss of heterozygosity in tumours or immunohistochemistry abnormalities considered functional evidence of pathogenicity. -
not specified Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingCenter for Genomic Medicine, Rigshospitalet, Copenhagen University HospitalFeb 06, 2024- -
Uncertain significance, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpOct 19, 2022Variant summary: ATM c.7775C>G (p.Ser2592Cys) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 250918 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.7775C>G has been reported in the literature as a heterozygous carrier genotype in individuals with a variety of cancers such as breast, non-Hodgkin lymphoma (NHL), Multiple primary tumors (MPTs), Prostate Cancer and other ATM-associated tumors (example, Dork_2001, Scott_2002, Bremer_2003, Meyer_2004, Sipahimalni_2007, Whitworth_2018, Karlsson_2021). These report(s) do not provide unequivocal conclusions about association of the variant with Ataxia-Telangiectasia/ATM-related cancers. At least one publication reports experimental evidence evaluating an impact on protein function demonstrating 1. a lack of ATM-kinase activity in vitro, 2. dominantly interfered with ATM kinase activity in wild type cells by preventing activation of endogenous ATM kinase in vitro and in vivo, 3. failed to correct the radiosensitivity and elevated chromosomal abberations in AT1ABR cells, lastly, 4. cells transfected with S2592C showed enhanced sensitivity to radiation similar to that of an AT cell line (Scott_2002). However, the data as presented in this study were not quantified to a residual activity. This study has been widely cited listing this as a "Kinase Dead" (KD) variant of ATM (example, Putti_2021). Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 (VUS, n=7; LP, n=1). Some submitters cite overlapping evidence utilized in the context of this evaluation. Based on the evidence outlined above, until additional consensus opinions around this variant evolve, the variant was classified as uncertain significance. -
Ataxia-telangiectasia syndrome Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpOct 02, 2022This sequence change replaces serine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 2592 of the ATM protein (p.Ser2592Cys). This variant is present in population databases (rs755009196, gnomAD 0.004%). This missense change has been observed in individual(s) with breast cancer, prostate cancer, or Non-Hodgkin's lymphoma (PMID: 11606401, 11805335, 17640065, 19781682, 28825054, 29909963). ClinVar contains an entry for this variant (Variation ID: 186713). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects ATM function (PMID: 11805335). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Uncertain significance, no assertion criteria providedclinical testingNatera, Inc.Jun 08, 2021- -
not provided Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingGeneDxJul 20, 2022Published functional studies suggest a damaging effect: absent kinase activity, increased radiosensitivity in vitro, and dominant interfering effect (Scott et al., 2002); Reported in individuals with breast or prostate cancer, but also in healthy controls (Dork et al., 2001; Tavtigian et al., 2009; Caminsky et al., 2016; Abida et al., 2017; Decker et al., 2017; Karlsson et al., 2021); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 19781682, 11606401, 15279808, 14643952, 16652348, 21910157, 12552566, 18568480, 16112413, 11839094, 12810666, 12969974, 21787400, 12511424, 20346647, 15450731, 28825054, 28779002, 28873162, 26898890, 29909963, 27535533, 33436325, 11805335) -
Uncertain significance, criteria provided, single submitterclinical testingMayo Clinic Laboratories, Mayo ClinicMay 28, 2020- -
Familial cancer of breast Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingBaylor GeneticsNov 21, 2023- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.087
BayesDel_addAF
Pathogenic
0.30
D
BayesDel_noAF
Pathogenic
0.30
CADD
Uncertain
25
DANN
Uncertain
0.99
DEOGEN2
Benign
0.27
T;T
Eigen
Pathogenic
0.70
Eigen_PC
Uncertain
0.64
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Benign
0.79
T;.
M_CAP
Pathogenic
0.31
D
MetaRNN
Pathogenic
0.91
D;D
MetaSVM
Uncertain
0.54
D
MutationAssessor
Uncertain
2.4
M;M
MutationTaster
Benign
1.0
D;D;D
PrimateAI
Benign
0.48
T
PROVEAN
Uncertain
-2.5
D;D
REVEL
Pathogenic
0.77
Sift
Uncertain
0.0010
D;D
Sift4G
Uncertain
0.0020
D;D
Polyphen
1.0
D;D
Vest4
0.62
MutPred
0.78
Loss of phosphorylation at S2592 (P = 0.0326);Loss of phosphorylation at S2592 (P = 0.0326);
MVP
0.96
MPC
0.54
ClinPred
0.91
D
GERP RS
5.4
Varity_R
0.37
gMVP
0.42

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs755009196; hg19: chr11-108202751; API